Home

JAY T FLATLEY

CIK 1189130 · Chairman and Acting CEO · last filed 2026-06-23

JAY T FLATLEY is a Chairman and Acting CEO who has filed 354 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing, for RIVN, was dated Jun 23, 2026. Across all open-market trades the lifetime net is −$492.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $44.2M across reported positions. 281 SEC filings were submitted jointly with ILLUMINA, INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$44.22M

Companies

6

Total Filings

354

Lifetime Open-Market Net

-$491.98M

Filer Profile

Reported Address
9885 TOWNE CENTRE DR
SAN DIEGO, CA 92121
Related Filers
ILLUMINA, INC. — 281 joint filings, latest 2021-05-20
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
RIVN Director 179,515 $15.54 $2.79M $2.75M 8 2026-06-23
DNLI Director 358,941 $20.38 $7.32M $0 12 2026-06-05
Zymergen Inc. (ZY) Delisted Chairman and Acting CEO 0 $2.43 $0 $1.00M 4 2022-10-19
COHR Director 856 $271.17 $232.1K -$2.07M 22 2022-07-01
ILMN Director 152,433 $222.29 $33.88M -$494.38M 303 2021-05-20
Juno Therapeutics, Inc. (JUNO) Delisted Director 0 — — $724.4K 5 2018-03-07

Recent Filings

354 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-23 RIVN Grant (A) +17,445 $0 EDGAR
2026-06-05 DNLI Grant (A) +6,408 $0 EDGAR
2026-03-05 RIVN Mixed +1,250 $13.5K EDGAR
2025-06-20 RIVN Grant (A) +16,812 $0 EDGAR
2025-06-05 DNLI Grant (A) +6,037 $0 EDGAR
2024-06-21 RIVN Grant (A) +24,224 $0 EDGAR
2024-06-04 DNLI Grant (A) +5,967 $0 EDGAR
2023-06-23 RIVN Grant (A) +18,208 $0 EDGAR
2023-06-05 DNLI Grant (A) +4,216 $0 EDGAR
2022-10-19 Zymergen Inc. (ZY) Delisted Disp (D) −144,789 $0 EDGAR
Showing 1–10 of 354
Page 1 of 36
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.